Online citations, reference lists, and bibliographies.
← Back to Search

Long-lasting Recovery In CD4 T-cell Function And Viral-load Reduction After Highly Active Antiretroviral Therapy In Advanced HIV-1 Disease

T. Li, R. Tubiana, C. Katlama, V. Calvez, H. A. Mohand, B. Autran
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND Highly active antiretroviral therapy (HAART) decreases viral load and increases CD4 T-cell counts in patients with advanced HIV-1 infection. Whether HAART can improve CD4 T-cell function, and the biological characteristics affecting immune reconstitution, remain unclear. We undertook an open prospective pilot study to address these issues. Both treatment-naïve and previously treated patients were included. METHODS 20 patients (seven naïve, 13 previously treated) were treated with one protease inhibitor and two reverse-transcriptase inhibitors and followed up for 12 months. We measured CD4-cell proliferation in response to cytomegalovirus and tuberculin antigens and counted subsets of CD4 cells at baseline and months 1, 3, 6, 9, and 12. Patients who had no antigen-specific reactivity at baseline but developed it while receiving HAART were classified as immunological responders. FINDINGS Four patients had antigen-specific reactivity at baseline compared with 14 at month 12 (p <0.001). Between month 3 and month 12 viral load fell by a median of 1.5 log copies/mL from baseline (4.6 log copies/mL) and CD4-cell count increased by a median of 63/microL (from 93/microL). Ten patients (six of seven naïve, four of 13 previously treated) were immunological responders. They differed significantly from the ten non-responders in that their viral-load reduction was sustained for 12 months, the increase in CD4 count was greater, and they showed an early increase in memory CD4 T cells with an increase of naïve T cells. INTERPRETATION HAART can induce sustained recovery of CD4 T-cell reactivity against opportunistic pathogens in severely immunosuppressed patients. This recovery depends not on baseline values but on the amplitude and duration of viral-load reduction and the increase of memory CD4 T cells.
This paper references
10.1016/0002-9343(85)90332-8
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome.
H. Lane (1985)
Early effects of HIV on CD4 lymphocytes in vivo.
J. Giorgi (1987)
10.1093/INFDIS/158.5.1071
Functional versus phenotypic analysis of T cells in subjects seropositive for the human immunodeficiency virus: a prospective study of in vitro responses to Cryptococcus neoformans.
J. Hoy (1988)
10.1093/INFDIS/164.4.638
Augmentation of cellular immune function during the early phase of zidovudine treatment of AIDS patients.
C. Rinaldo (1991)
10.1093/INFDIS/166.4.723
Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients.
M. Clerici (1992)
10.1097/00002030-199211000-00009
Zidovudine‐induced restoration of cell‐mediated immunity to mycobacteria in immunodeficient HIV‐infected patients
M. French (1992)
10.1093/INFDIS/172.1.79
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus.
M. Dolan (1995)
10.1056/NEJM199604183341602
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
A. Collier (1996)
10.1093/INFDIS/173.2.321
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
A. Kelleher (1996)
10.1016/S0140-6736(05)62505-6
Decline in deaths from AIDS due to new antiretrovirals
R. Hogg (1997)
10.1016/S0952-7915(97)80112-4
Immune reconstitution in HIV infection.
S. Emery (1997)
10.1056/NEJM199709113371102
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
R. Gulick (1997)
10.1038/NM0597-533
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
M. Connors (1997)
10.1016/S0140-6736(96)11431-8
Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
M. Jacobson (1997)
10.1126/SCIENCE.277.5322.112
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
B. Autran (1997)
10.1056/NEJM199709113371101
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
S. Hammer (1997)
10.1038/387188A0
Decay characteristics of HIV-1-infected compartments during combination therapy
A. Perelson (1997)
Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
D. Mathez (1997)
10.1016/S0002-9394(14)70784-6
Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS.
G. Tanguilig (1998)
10.1038/nm0298-215
Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
G. Gorochov (1998)



This paper is referenced by
10.1186/s12981-021-00370-y
Associations between antiretroviral therapy-related experiences and mental health status among people living with HIV in China: a prospective observational cohort study
Jinzhao Xie (2021)
10.1016/j.cellimm.2021.104396
GALT CD4+PD-1hi T follicular helper (Tfh) cells repopulate after anti-retroviral therapy.
O. Onabajo (2021)
10.1128/mBio.00568-21
Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in Children
M. Bale (2021)
10.1186/s12879-021-06260-y
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
E. Merlini (2021)
10.3389/fgene.2021.641905
Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions
Yueran Li (2021)
10.1101/2020.09.15.298406
Early Emergence and Long-Term Persistence of HIV-Infected T Cell Clones in Children
M. Bale (2020)
HIV-1 TAT Interactions with Opioids are Modulated by Progesterone and Estradiol
Dejun Jackson (2020)
10.2174/1570162X18666200620211922
The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro.
Xu-Sheng Huang (2020)
10.1007/s13365-020-00848-x
Progressive multifocal leukoencephalopathy despite immune recovery in a HIV/HCV co-infected patient
M. Hentzien (2020)
10.3389/fimmu.2019.00463
Altered Immunity and Microbial Dysbiosis in Aged Individuals With Long-Term Controlled HIV Infection
Nicholas A. Rhoades (2019)
10.1016/j.clnu.2018.05.014
Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial.
R. Shivakoti (2019)
10.1016/j.antiviral.2019.104552
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: Results from a multicenter cohort study.
B. Rossetti (2019)
10.1101/19011221
Influence of sexual risk behaviour and STI co-infection dynamics on the evolution of HIV set point viral load in MSM
Diana M. Hendrickx (2019)
10.1016/j.brainres.2019.146397
White matter loss and oligodendrocyte dysfunction in HIV: A consequence of the infection, the antiretroviral therapy or both?
Brigid K Jensen (2019)
10.1016/S2352-3018(19)30196-1
Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017
Tahvi D Frank (2019)
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2007)
Documento de Consenso (2019)
Analysis of the implementation of an antiretroviral treatment programme in KwaZulu- Natal province
Manyeke Jeanivive Sengwana (2019)
10.1371/journal.pone.0190487
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
D. Kerrigan (2018)
10.1038/s41401-018-0027-5
The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation
X. Zhang (2018)
10.1186/s12974-018-1244-z
Brain 18F-FDG PET of SIV-infected macaques after treatment interruption or initiation
William Schreiber-Stainthorp (2018)
10.22038/AJP.2017.18637.1721
The effects of setarud on the immunological status of HIV-positive patients: Efficacy of a novel multi-herbal drug
Mehdi Gholamzadeh Baeis (2017)
10.1016/j.ijom.2017.06.008
Impact of highly active antiretroviral therapy on the prevalence of oral lesions in HIV-positive patients: a systematic review and meta-analysis.
V. L. de Almeida (2017)
10.1089/AID.2016.0030
Dysregulation of Alveolar Macrophage PPARγ, NADPH Oxidases, and TGFβ1 in Otherwise Healthy HIV-Infected Individuals.
S. Yeligar (2017)
10.1080/14740338.2017.1270940
Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management
T. Shiohara (2017)
10.21615/CESMEDICINA.31.1.1
Effect of zinc on immune recovery in HIV patients. Medellín 2013. Randomized controlled trial
Heidy Contreras-Martínez (2017)
10.18632/oncotarget.21585
The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells
Hanyu Pan (2017)
10.1097/MD.0000000000007430
The investigation of CD4+T-cell functions in primary HIV infection with antiretroviral therapy
Y. Sun (2017)
10.1371/journal.pone.0164148
Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database
A. R. Means (2016)
10.1128/microbiolspec.TBTB2-0012-2016
The Immune Interaction between HIV-1 Infection and Mycobacterium tuberculosis.
E. Du Bruyn (2016)
10.1128/JVI.00612-16
CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo
M. Chachage (2016)
10.1097/QAI.0000000000000849
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy
A. Di Biagio (2016)
10.14499/INDONESIANJPHARM27ISS4PP211
Ameliorative effects of vitamins C and E on tenofovir/nevirapine-induced hepatorenal oxidative stress in albino rats
Elias Adikwu (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar